FDA-approved Product
Therapy Areas
Sanofi has approved therapies for the following cancer types:
- Blood: relapsed and/or refractory multiple myeloma (MM)
-
Prostate: metastatic castration-resistant prostate cancer (mCRPC)
Sanofi is also focused on hyperuricemia related to tumor lysis syndrome (TLS).
Educational Resources
General
Time to Screen: Information on Early Cancer Detection
TimeToScreen.org encourages and reminds people to take control of their health by getting recommended cancer screenings. The campaign is led by two national, non-profit organizations, Community Oncology Alliance (COA) and CancerCare.
Multiple Myeloma
Multiple Myeloma: Disease Overview
A presentation providing an overview of MM, including epidemiology, pathogenesis, diagnosis, staging and risk stratification, and response to therapy, including definitions and response criteria from the International Myeloma Working Group (IMWG). The presentation highlights minimal residual disease as an important prognostic factor in MM. There is also a brief introduction to the patient perspective.
Minimal Residual Disease in Multiple Myeloma
One in a series of PDFs that provide education on relevant topics in MM. This edition focuses on minimal residual disease (MRD), and includes an overview of MRD and the impact of achieving early and sustained MRD negativity on patient prognosis and outcomes.
Associated Clinical Guidelines and Recommendations
NCCN | National Comprehensive Cancer Network | 2023
IMWG: Treatment | International Myeloma Working Group | 2021
IMWG: Response Criteria | International Myeloma Working Group | 2016
IMWG: Renal Impairment | International Myeloma Working Group | 2023
Prostate Cancer
The Changing Landscape of Metastatic Castration-Resistant Prostate Cancer: Where Are We Today?
A presentation providing a brief overview of the progression of prostate cancer to mCRPC, high-risk categories of mCRPC, monitoring recommendations, recent therapeutic advances, and the complexities of therapeutic sequencing.
Associated Clinical Guidelines and Recommendations
NCCN | National Comprehensive Cancer Network | 2023
Tumor Lysis Syndrome
Tumor Lysis Syndrome Risk Analysis in a US Community Oncology Setting: A Retrospective Observational Study in Integra Connect Network
A presentation summarizing results from a retrospective, real-world, observational, electronic medical record analysis of the Integra Connect Database of risk factors by tumor type for the development of TLS. These data were presented at the National Comprehensive Cancer Network (NCCN) 2021 Annual Conference.
Tumor Lysis Syndrome (TLS) Fatalities Poster Video Overview
A three-minute video overview of a TLS mortality poster that was presented at SOHO 2022. This real world study compared TLS-associated morbidities after anti-hyperuricemic monotherapy with rasburicase vs allopurinol in patients with hematologic malignancies at risk for TLS.
Associated Clinical Guidelines and Recommendations
Perissinotti et al. | Expert Panel Consensus | 2023
Sanofi does not review or control the content of non-Sanofi websites.